Using AI to determine drug compounds to curb the opioid crisis
Researchers have developed a computer model, that learns using AI, to identify potential drug compounds that can be used to block opioid receptors in the brain.
In the USA, the opioid crisis has been a feature for decades, with three million people suffering from opioid use disorder, and over 80,000 Americans dying from overdoses each year.
Drugs in the opioid family – heroin, oxycodone, fentanyl, and morphine – work by activating µ-opioid receptors in the brain, which provides relief from pain and gives a state of euphoria. Alongside this however, is physical dependence on the opioid and decreased breathing rate, which in the event of an overdose can drop so dramatically as to cause death.
Physical dependence has been shown to decrease when k-opioid receptors – the receptors that mediate brain rewards – are blocked, in preclinical studies. By discovering drug that block these receptors, there could be a real opportunity to tackle opioid dependence, and curb the crisis.
Leslie Salas Estrada, part of the Filizola Lab, at the Icahn School of Medicine at Mount Sinai (NY, USA), will present her work on the subject at the 67th Annual Biophysical Society Meeting in San Diego, CA, USA in February.
“If you're addicted and you're trying to quit, at some point you will get withdrawal symptoms, and those can be really hard to overcome,” Salas Estrada explained, “after a lot of opioid exposure, your brain gets rewired to need more drugs. Blocking the activity of the kappa opioid receptor has been shown in animal models to reduce this need to use drugs in the withdrawal period.”
Unfortunately, to discover new drugs that do this can be like trying to find a needle in a haystack, which can be time consuming, costly, and fruitless, even when using computational models to screen compounds. This is where artificial intelligence (AI) comes in.
“Artificial intelligence has the advantage of being able to take huge amounts of information and learn to recognize patterns from it. So, we believe that machine learning can help us to leverage the information that can be derived from large chemical databases to design new drugs from scratch. And in that way, we can potentially reduce the time and costs associated with drug discovery,” stated Salas Estrada.
By using what the researchers already know about the k-opioid receptor, and the existing drugs on the market, they can populate a computer model with this information, and use AI to manipulate the model, along with a learning algorithm that rewards compounds with properties that make them appealing as drug treatments, to generate prospective compounds.
Using this method the team at Icahn School of Medicine at Mount Sinai have been able to identify numerous promising compounds, with the complimentary properties, with the hopes of testing them. This should be made possible once the drugs have been synthesised, their safety and efficacy in blocking k-opioid receptors assessed first in cell models and then in animal models.
Salas Estrada concluded, “we hope we can help people struggling with addiction.”
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance